Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Plus Irinotecan in Pediatric Recurrent Brain Tumors
NCT00381797Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2006
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in malignant glioma, diffuse intrinsic brainstem glioma (DIPG), medulloblastoma and 2 more, sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate Sustained for >= 8 Weeks at 24 weeks and Sustained Disease Stabilization Rate at 24 weeks. Started Aug 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
malignant gliomadiffuse intrinsic brainstem glioma (DIPG)medulloblastomaependymomalow-grade glioma (LGG)
Beyond the preview
Go deeper on NCT00381797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381797.